Subtype switching further contributes to treatment adaptation: loss of hormone receptor expression in HR+ CTCs correlates with poor prognosis under endocrine therapy [86], whereas detection of HER2+ CTCs in HER2− breast cancer may predict sensitivity to anti-HER2 agents [6]. Here, ERBB2 is linked to breast carcinoma.